drugset / Trial / NCT00242580
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib added as an intravitreal injection.
Timeline
- Start
- 2005-09
- Primary completion
- 2008-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Triamcinolone Acetonide | Other / unclassified | 1 mg | Intravitreal |
| Subject | Triamcinolone Acetonide | Other / unclassified | 4 mg | Intravitreal |
| Comparator | pegaptanib sodium | Aptamer | 0.3 mg | Intravitreal |
| Background | Verteporfin | Other / unclassified | 6 mg/m2 | Intravenous |